Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY):
Imprimis Launches Surface Pharmaceuticals Subsidiary.
The company is so far trading down by 1.62% percent from yesterday’s close.
Imprimis Pharmaceuticals, Inc. (Imprimis), launched on January 11, 2006, is involved in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases..
Company shares are trading at $1.82 a bit higher than $1.68, the 50 day moving average and much lower than the 200 day moving average of $2.80. The 50 day moving average moved up $0.14 whereas the 200 day average was down by -34.91%.
Traders are feeling more bullish on shares of Imprimis Pharmaceuticals, Inc. at least if you consider the downtick in short interest. The firm realized a fall in short interest from September 15, 2017 to September 29, 2017 of -10.10%. Short shares decreased from 791,589 to 711,604 over that period. With short interest at 711,604 and short average daily volume at 74,517, days to cover is 10.0 and the percentage of shorted shares was 0.04% on September 29.